Skin Fibroblasts from Individuals Self-Diagnosed as Electrosensitive Reveal Two Distinct Subsets with Delayed Nucleoshuttling of the ATM Protein in Common
Laurène Sonzogni(Inserm), Nicolas Foray(Inserm), P. Combemale(Centre Léon Bérard), Amélie Massardier-Pilonchery(Unité Mixte de Recherche Epidémiologique et de Surveillance Transport Travail Environnement), Audrey Bouchet(Inserm), J F Doré(Inserm), Yves Le Dréan(Inserm), Jean‐Claude Debouzy(Institut d'Imagerie Biomédicale), Joëlle Al-Choboq(Inserm), Michel Bourguignon(Centre Hospitalier d'Orsay)
Cited by 2
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192
Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966
|Orphanet Journal of Rare Diseases|2020|188